Intravascular Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Intravascular Stents Market is projected to expand from a valuation of USD 13.22 Billion in 2025 to USD 20.28 Billion by 2031, registering a CAGR of 7.39% during this period. These devices, which are expandable mesh tubes utilized to reopen narrowed or blocked arteries, are essential for restoring blood flow and ensuring vessel patency. The primary growth factors include a rapidly aging global population and a growing incidence of cardiovascular diseases, which increase the necessity for interventional procedures to treat conditions like coronary artery disease. Data from the European Society of Cardiology indicates that in 2024, cardiovascular disease caused more than 3 million deaths annually across member nations, underscoring the urgent and continuing need for effective therapeutic solutions.

Conversely, the market encounters significant hurdles arising from strict regulatory frameworks regarding safety standards and product approvals. Regulatory bodies mandate exhaustive clinical testing, which prolongs development timelines and increases manufacturing costs before devices can enter the commercial market. Furthermore, the risk of product recalls triggered by adverse events, such as thrombosis, poses a serious threat to brand reputation and can delay the market adoption of emerging technologies.

Market Drivers

The rising global prevalence of cardiovascular diseases acts as the main driver for the intravascular stents industry, necessitating a higher volume of angioplasty procedures to treat arterial obstructions. As poor dietary choices and sedentary lifestyles become more widespread, rates of coronary artery disease are increasing, requiring mechanical interventions to maintain adequate blood flow. According to the 'Vital Statistics Rapid Release' report published by the Centers for Disease Control and Prevention in September 2025, heart disease remained the primary cause of mortality in 2024, responsible for 683,037 deaths in the United States alone. This ongoing health burden ensures steady demand for therapeutic devices, a trend reflected in industry performance; Medtronic’s 'Fiscal Year 2025 Annual Report' from June 2025 noted that their Cardiovascular Portfolio achieved $12.5 billion in net sales, highlighting the critical global need for these interventions.

Additionally, technological innovations in stent materials and design represent a significant growth driver, with manufacturers launching next-generation devices that enhance patient recovery and broaden the treatable population. Developments such as drug-eluting technologies and bioresorbable scaffolds have notably lowered the risks of thrombosis and restenosis compared to earlier bare-metal models, enabling physicians to address peripheral vascular conditions and complex lesions that were previously challenging to treat. Continuous R&D investment is generating substantial returns for major companies; for example, Abbott’s 'Fourth-Quarter and Full-Year 2024 Results' from January 2025 reported a 13.7% growth in their Medical Devices segment, fueled partly by a surge exceeding 20% in Structural Heart revenue involving advanced scaffold technologies. This product evolution encourages healthcare facilities to upgrade their supplies, thereby maintaining revenue growth and market momentum.

Market Challenges

The strict regulatory frameworks that govern safety standards and product approvals constitute a major obstacle to the expansion of the Global Intravascular Stents Market. Worldwide regulatory bodies impose demanding quality assurance and clinical testing mandates that manufacturers must fulfill prior to commercializing a device. These extensive requirements significantly prolong the product development lifecycle and elevate financial costs, frequently forcing companies to divert funds away from research and development initiatives. This complicated regulatory environment slows the introduction of innovative stent technologies and limits their availability in critical geographic regions.

Data from MedTech Europe in 2024 indicates that under the new regulatory landscape, the average timeframe for medical device certification has increased to between 13 and 18 months, while compliance costs have risen by roughly 100% compared to earlier directives. These delays and increased expenses compel manufacturers to reassess their market strategies, often resulting in the withdrawal of legacy products or the deprioritization of regions with high regulatory barriers. Consequently, the sluggish approval process directly impedes market growth and restricts the timely accessibility of advanced therapeutic options for patients suffering from cardiovascular conditions.

Market Trends

The migration of procedures toward Ambulatory Surgical Centers (ASCs) is fundamentally reshaping the procurement landscape, influenced by the demand for cost-effective healthcare and evolving reimbursement policies. Healthcare systems are increasingly moving percutaneous coronary interventions (PCIs) from inpatient hospital settings to outpatient facilities to reduce procedural costs and manage hospital capacity issues.

This transition is bolstered by regulatory changes, such as the broadening of CMS covered procedure lists, which encourage providers to conduct catheter-based interventions in these more economical settings; consequently, manufacturers are adjusting their supply chains to meet the specific logistical and inventory requirements of high-volume outpatient centers. According to the 'State of the Industry Report' by HST Pathways in March 2025, cardiology represented 24% of total ASC block time utilization in 2024, indicating a rapid shift toward prioritizing vascular interventions in these facilities.

Concurrently, the integration of artificial intelligence into stent selection and sizing is transforming pre-procedural planning by improving device deployment precision. Advanced algorithms are being combined with intravascular imaging tools, like Optical Coherence Tomography (OCT), to automate the assessment of lesion characteristics and vessel dimensions. This technological advancement tackles critical issues such as stent underexpansion and malapposition, which are primary causes of restenosis and device failure. By utilizing machine learning to analyze complex imaging data, clinicians can identify the ideal landing zone and stent size with superior accuracy, enhancing long-term outcomes; a review titled 'Harnessing Artificial Intelligence in Interventional Cardiology' by the National Institutes of Health in July 2025 noted that deep learning algorithms achieved 94% accuracy in predicting incomplete stent expansion, highlighting the capacity of these tools to reduce procedural errors.

Key Players Profiled in the Intravascular Stents Market

• Boston Scientific Corporation
• Medtronic plc
• Terumo Medical Corporation
• Abbott Laboratories Inc.
• BIOTRONIK SE & Co. KG
• Stryker Corporation
• Microport Scientific Corporation
• Stentys S.A.
• HELLMAN & FRIEDMAN LLC
• B. Braun SE

Report Scope

In this report, the Global Intravascular Stents Market has been segmented into the following categories:

Intravascular Stents Market, by Type:

• Drug Eluting Stents
• Bare Metal Stents
• Bioabsorbable Stents

Intravascular Stents Market, by Product:

• Coronary Stents
• Peripheral Stents

Intravascular Stents Market, by End-Use:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Intravascular Stents Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravascular Stents Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.